
China Development Industrial Bank (CDIB)
Description
CDIB, originally China Development Industrial Bank, has evolved significantly from its roots as a development bank and early-stage venture capital investor in Taiwan. Established in 1959, the institution played a pivotal role in fostering Taiwan's industrial and technological growth. In 2005, its direct investment business spun off to form CDIB Capital Group, which has since transformed into a prominent private equity firm. While the group acknowledges a long track record of investing across various stages, including early-stage venture capital, its current primary focus is on growth capital and buyouts across Greater China and Asia.
CDIB Capital Group manages substantial assets, with over US$2.6 billion under management as of recent reports. The firm has a robust history of deploying capital, having invested over US$2.5 billion across more than 100 companies since its inception. Its investment strategy spans critical sectors such as TMT (Technology, Media, and Telecommunications), healthcare, consumer, advanced manufacturing, new materials, and clean energy. The group's latest flagship fund, CDIB Capital Asia Partners IV, successfully closed at US$1.05 billion in 2023, underscoring its capacity for large-scale investments.
For its typical private equity transactions, CDIB Capital Group generally invests between US$10 million and US$50 million per deal. While its historical venture capital activities were instrumental in its early days, the firm's current operational model and fund structures are geared towards larger growth equity and buyout opportunities. This strategic shift allows CDIB Capital Group to support established companies seeking expansion capital or facilitate ownership changes, leveraging its extensive network and deep industry expertise across the Asian markets.
Investor Profile
China Development Industrial Bank (CDIB) has backed more than 52 startups, with 0 new investments in the last 12 months alone. The firm has led 6 rounds, about 12% of its total and boasts 31 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series Unknown, Series C rounds (top funding stages).
- Majority of deals are located in United States, Taiwan, Israel.
- Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
- Typical check size: $10M – $50M.
Stage Focus
- Series B (31%)
- Series Unknown (21%)
- Series C (17%)
- Series D (13%)
- Series A (10%)
- Private Equity (4%)
- Post Ipo Equity (2%)
- Series E (2%)
Country Focus
- United States (88%)
- Taiwan (8%)
- Israel (2%)
- China (2%)
Industry Focus
- Biotechnology
- Health Care
- Pharmaceutical
- Medical
- Semiconductor
- Security
- Biopharma
- Software
- Enterprise Software
- Wireless
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.